Strive Q3 2026 earnings

ASST · 2026-11-06 08:00 BMO ET · 8-K on SEC · 10-Q on SEC

Net income of $509.0 million driven by a $533.7 million unrealized gain on digital assets.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$2.70B+106.5%-8.3%Ex. 99.1, income statement
EPS (GAAP)$5.24+235.5%+139.0%Ex. 99.1, income statement
EPS (adjusted)$5.46+271.4%+49.6%Ex. 99.1, income statement
Net income$509.0M+4,860.0%+197.4%Ex. 99.1, income statement
Adj. EBITDA$513.5M+4,860.0%+197.4%Ex. 99.1, income statement
Adj. EBITDA margin19.0%+19.0 pp+2.1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Investment advisory fees$1.56B+21.5%57.9%—
Medical device revenues$1.13B—42.1%—
Other revenue$4M-20.0%0.1%—

Margins and costs

  • Gross margin 19.0% (prior 16.9%, change +2.1 pp)
  • Operating expenses $38.70B (+24.6% YoY)
  • One-offs in the quarter Impairment of medical device research and development intangible asset: $14.65M; Goodwill and intangible asset impairment: $140.79M
  • Effective tax rate 0.0% (prior-year 0.0%, year-to-date 0.0%)
  • Non-GAAP bridge Adds back share-based compensation ($6.52M), impairment ($14.65M), goodwill ($140.79M), transaction costs ($6.53M), and bargain purchase gain ($66.70M) to GAAP net income.

KPIs

MetricActualPrior quarterPrior yearChange
Bitcoin Yield23.9%23.9%37.7%-13.8 pp
Cash and cash equivalents$490.4M$154.9M$0+217.0%
Digital assets, at fair value$2.34B$2.34B$00.0%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Investment advisory fees grew 21.5% YoY to $1.56B; medical device revenues grew 21.5% YoY to $1.13B; other revenue declined 20.0% YoY to $4M.
  • EPS story EPS growth driven by a $533.7 million unrealized gain on digital assets and a $8.8 million gain on investments in preferred equity.
  • One-off check Impairment of medical device R&D intangible asset ($14.65M) and goodwill and intangible asset impairment ($140.79M).

The good

  • Net income of $509.0 million driven by a $533.7 million unrealized gain on digital assets.
  • Adjusted EBITDA margin expanded to 19.0% (+2.1 pp YoY).

The bad

  • Medical device R&D intangible asset impairment of $14.65M.
  • Goodwill and intangible asset impairment of $140.79M.

The ugly

  • none

Open questions

  • The release references a 'Bitcoin accumulation results' section but does not provide the specific Bitcoin yield percentage for Q3.
  • The release mentions evaluating opportunities to leverage its balance sheet (banking, brokerage, etc.) but does not disclose any specific commitments or capital allocation.
Full release

Strive (ASST) earnings release, November 6, 2026

Strive, Inc. (ASST) · Form 8-K, Item 2.02 · Filed · SEC filing

1

Strive, Inc. Announces

Third

Quarter 2026 Financial Results

DALLAS, TX — (GLOBE NEWSWIRE) — November 6, 2026

- Strive, Inc. (Nasdaq: ASST; SATA; SATS) (“Strive” or the

“Company”) today announced its financial results for the third quarter ended

September 30, 2026.

Key

Highlights:

▪ Acquired a total of

8,136 bitcoin during the third quarter ended

September 30, 2026 and

20,373 bitcoin during the nine months ended September 30, 2026.

▪ Acquired an additional

15,124 bitcoin during the period from

October 1, 2026 through

October 30, 2026.

▪ Achieved the following Bitcoin accumulation results:

▪ As of

October 30, 2026, Strive's cash and cash equivalents totaled

$490.4 million and our position in Variable Rate Series

A Perpetual Preferred Stock of Strategy Inc. ("STRC Stock") had a fair value of

$50.1 million. Strive had

118,117,620 and

9,213,489 shares of Class A common stock and Class B common stock, respectively, and

14,030,176 and

7,003,418 shares of Variable Rate Series A Perpetual Preferred Stock ("SATA Stock") and

15.00% Series A Perpetual SATS

Preferred Stock ("

SATS Stock"), respectively, outstanding as of

October 30, 2026.

▪ On October 20, 2026, completed a registered public offering of 7,000,000 shares of its SATS Stock, for net proceeds of approximately $609.0 million, after deducting the underwriting discounts and commissions. The SATS Stock is listed for trading on the Nasdaq Global Market under the symbol “SATS.”

▪ GAAP net income of

$509.0 million for the three months ended September 30, 2026. Net income per common share for the same period was

$5.24 on a fully diluted basis.

▪ Non-GAAP adjusted net income attributable to common stockholders¹ of

$494.6 million, or

$5.46 per diluted common share¹, for the three months ended September 30, 2026. Non-GAAP adjusted net income attributable to common stockholders subtracts non-recurring and non-cash items from GAAP net loss attributable to common stockholders.

▪ As part of its overall investment strategy, the Company is evaluating various opportunities to leverage its balance sheet, including banking, brokerage, decentralized finance, reinsurance, structured ABS, and tokenization, among other opportunities, taking into account underwriting conditions, tax implications, regulatory considerations, alignment with its broader investment objectives, and other relevant factors.

"Strive has continued to successfully execute on its treasury management strategy, delivering a strong bitcoin yield year to date in

2026, which I believe is the primary driver of our common equity's outperformance relative to Bitcoin so far this year," said

Matthew Cole, Chairman & Chief Executive Officer of Strive, Inc. "With the recent issuance of SATS, we believe Strive has never been in a better position to generate long-term returns in excess of Bitcoin for our common equity shareholders."²

STRIVE, INC.

CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION

(in thousands, except share and per share data)³

Financial statements

Income Statement

(unaudited)

Successor – Three Months Ended September 30, 2026Successor – Period From September 12, 2025 to September 30, 2025Predecessor – Period From July 1, 2025 to September 11, 2025
Revenues:
Investment advisory fees1,5592461,283
Medical device revenues1,133
Other revenue495
Total revenues2,6962551,288
Operating expenses:
Fund management and administration1,5832821,251
Employee compensation and benefits15,63318,7203,151
General and administrative expense6,669445871
Impairment of medical device research and development intangible asset14,650
Marketing and advertising861868
Depreciation and amortization781243
Total operating expenses38,69919,4775,384
Investment gains (losses):
Net unrealized gain (loss) on digital assets, at fair value533,697-10,133
Net unrealized gain on investments in preferred equity, at fair value8,833
Other investment gain1,497
Other derivative loss-14,731
Total investment gains (losses)544,027-24,864
Net operating income (loss)508,024-44,086-4,096
Other income (expense):
Other income1,0086810
Goodwill and intangible asset impairment-140,785
Transaction costs-7,484-10,280
Total other income (expense)1,008-148,201-10,270
Net income (loss) before income taxes509,032-192,287-14,366
Net income (loss)509,032-192,287-14,366
Dividends on preferred stock-34,231
Net income (loss) attributable to common stockholders474,801-192,287-14,366
Weighted average number of common shares outstanding:
Basic (1)89,080,30343,617,4592,325,783
Diluted (1)90,534,79843,617,4592,325,783
Net income (loss) per common share:
Basic (1)5.33-4.41-6.18
Diluted (1)5.24-4.41-6.18

Income Statement

(in thousands, except share and per share data)

Successor – Nine Months Ended September 30, 2026 – (unaudited)Successor – Period From September 12, 2025 to September 30, 2025 – (unaudited)Predecessor – Period From January 1, 2025 to September 11, 2025 – (audited)
Revenues:
Investment advisory fees4,4182464,187
Medical device revenues3,891
Other revenue88935
Total revenues8,3972554,222
Operating expenses:
Fund management and administration4,4962824,250
Employee compensation and benefits45,00018,7207,222
General and administrative expense19,0354454,229
Impairment of medical device research and development intangible asset14,650
Marketing and advertising28118231
Depreciation and amortization25412149
Total operating expenses83,71619,47716,081
Investment gains (losses):
Net unrealized gain (loss) on digital assets, at fair value9,888-10,133
Net unrealized gain on investments in preferred equity, at fair value3,361
Other investment loss-1,304
Other derivative loss-14,731
Total investment gains (losses)11,945-24,864
Net operating loss-63,374-44,086-11,859
Other income (expense):
Other income2,48968586
Interest expense on long-term notes payable, at fair value-282
Change in fair value on long-term notes payable, at fair value-2,464
Loss on extinguishment of debt-8,431
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan-2,594
Goodwill and intangible asset impairment-140,785
Transaction costs-6,525-7,484-15,717
Bargain purchase gain66,704
Total other income (expense)48,897-148,201-15,131
Net loss before income taxes-14,477-192,287-26,990
Net loss-14,477-192,287-26,990
Dividends on preferred stock-73,894
Net loss attributable to common stockholders-88,371-192,287-26,990
Weighted average number of common shares outstanding:
Basic (1)75,429,25443,617,4592,299,243
Diluted (1)75,429,25443,617,4592,299,243
Net loss per common share:
Basic (1)-1.17-4.41-11.74
Diluted (1)-1.17-4.41-11.74

Income Statement

than share and per share information):

Successor – Three Months Ended September 30, 2026Successor – Nine Months Ended September 30, 2026Successor – Period From September 12, 2025 to September 30, 2025Predecessor – Period From July 1, 2025 to September 11, 2025Predecessor – Period From January 1, 2025 to September 11, 2025
Net income (loss)509,032-192,287-14,366
Share-based compensation expense6,52316,294

Balance Sheet

September 30, 2026 — (in thousands, except share and per share data)

September 30, 2026 – (unaudited)December 31, 2025 – (audited)
Current assets:
Cash and cash equivalents285,40567,499
Investments in preferred equity, at fair value50,172
Prepaid expenses1,0342,708
Other current assets2,0721,569
Total current assets338,68371,776
Digital assets, at fair value2,340,192668,486
Property and equipment, net731778
Intangible assets, net321355
Right-of-use lease assets3,7174,037
Other non-current assets52695
Total assets2,684,170745,527
Current liabilities:
Compensation and benefits payable12,924164
Accounts payable and other liabilities7,3568,560
Dividends payable14,0222,053
Total current liabilities34,30210,777
Operating lease liabilities3,2183,512
Total liabilities37,52014,289
Mezzanine equity:
Variable Rate Series A Preferred Stock, $0.001 par value; 40,000,000 and 20,000,000 shares authorized, 12,940,621 and 2,012,729 shares issued and outstanding, $1.3 billion and $201.3 million liquidation preference as of September 30, 2026 and December 31, 2025, respectively1,210,820148,802
Total mezzanine equity1,210,820148,802
Stockholders’ equity:
Class A common stock, $0.001 par value; 22,200,000,000 shares authorized, 88,814,706 and 34,936,745 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively89699
Class B common stock, $0.001 par value; 1,050,000,000 shares authorized, 9,198,036 and 9,776,540 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively9196
Additional paid-in capital1,998,1571,055,595
Accumulated deficit-562,425-474,054
Total stockholders’ equity1,435,830582,436
Total liabilities, mezzanine equity, and stockholders' equity2,684,170745,527

Cash Flow

From the 10-Q · (in thousands)

Successor – Nine Months Ended September 30, 2026 – (unaudited)Successor – Period From September 12, 2025 to September 30, 2025 – (unaudited)Predecessor – Period From January 1, 2025 to September 11, 2025 – (audited)
Cash flows from operating activities:
Net loss-14,477-192,287-26,990
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization25412149
Accretion of discount on investments, net155
Reduction of right-of-use lease assets and operating lease liabilities40591
Net unrealized gain (loss) on digital assets, at fair value-9,88810,133
Other investment loss1,304
Other derivative loss14,731

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.